RiboX reports early human results for circular RNA therapy

RiboX Therapeutics has reported early human results for its experimental circular RNA treatment RXRG001, with improved measures of salivary flow in six patients with radiation-induced dry mouth. The findings, published in the New England Journal of Medicine, offer preliminary clinical evidence for the approach but do not establish its effectiveness in a broader population.

The phase 1 report described adverse events as transient and grade 1 or 2. RiboX supported the research, according to the publication’s disclosures. The small patient group makes the findings an initial signal rather than a definitive assessment of either treatment benefit or safety.

RXRG001 contains circular RNA encoding human aquaporin-1, packaged inside lipid nanoparticles. According to RiboX, the treatment is designed to enable local production of that protein and restore fluid transport and saliva secretion in radiation-damaged glands. It is administered directly into the salivary glands rather than being developed as a general treatment for every cause of dry mouth.

The condition being targeted can follow radiation treatment for head and neck cancer. RiboX describes persistent dry mouth and reduced saliva production as complications that can interfere with eating, chewing, swallowing and speaking, while contributing to oral and dental problems. Its therapeutic goal is to restore gland function rather than focus solely on managing symptoms.

Endpoints News framed the publication as the first circular RNA clinical data and placed RiboX alongside developers Orna, Orbital and Sail Biomedicines. That reported milestone concerns the emergence of human evidence, not proof that one company’s technology is superior. The RXRG001 findings do not establish how other circular RNA medicines would perform in different diseases or with different delivery methods.

The broader study, called SPRINX-1, is evaluating safety, tolerability and preliminary efficacy in adults with radiation-induced xerostomia and reduced saliva production. Official trial descriptions identify it as a phase 1/2a dose-escalation study. Its first part is open-label and single-arm, with administration into one parotid gland across single-dose and multiple-dose groups.

The planned second part uses a randomized, double-blind, placebo-controlled design, with administration into both parotid glands. That comparison will be important for interpreting changes in symptoms and saliva production because an uncontrolled observation cannot by itself establish how much improvement is attributable to treatment. The six-patient publication should therefore be read within the context of an ongoing development program.

Further study will need to clarify the consistency and duration of any benefit, alongside the risks associated with treatment and repeat administration. Stanford’s trial listing describes recruitment for the program, while the study design provides for additional dose evaluation and controlled testing. Those subsequent results will determine whether the early signal translates into a more firmly supported treatment approach.